Business
AZN: Year-to-date and Q3 2020 results
AZN: Year-to-date and Q3 2020 results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3134E\n AstraZeneca PLC\n 05 November 2020\n \n \n \n AstraZeneca PLC\n 5 November 2020 07:00 GMT\n \n \n \n Year-to-date and Q3 2020 results\n On track to meet full-year guidance; executing the strategy of sustainable growth through innovation\n \n \n \n In the year to date, AstraZeneca delivered increases in the top line, profit and cash, underpinned by a strategy of sustainable growth through innovation. Total Revenue was in line with expectations and the operating performance continued to improve, with earnings growth in the third quarter reflecting Collaboration Revenue and Other Operating Income and Expense weighted towards the fourth quarter. As a result, full-year guidance remains unchanged.\n \n Pascal Soriot, Chief Executive Officer, commented:\n \"We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic. Highlights of the sales performance included further success in Oncology and an acceleration in the progress of Farxiga. Our pipeline also excelled, with Farxiga expanding its potential beyond diabetes and heart failure with ground-breaking new data in chronic kidney disease, while regulatory submission acceptance was achieved for anifrolumab in lupus.\n \n In the fight against COVID-19, we advanced our vaccine collaboration with the University of Oxford and are launching Phase III trials for our long-acting antibody combination for the prophylaxis and treatment against COVID-19 for people who need an immediate defence or whose weaker immune systems mean they are less likely to benefit from a vaccine.\n \n We continue to progress in line with our expectations and maintain our full-year guidance, which is underpinned by the strategy of sustainable growth through innovation.\"\n \n Table 1: Financial summary\n \n \n \n \n \n \n \n \n \n \n \n \n \n YTD 2020\n \n \n \n \n Q3 2020\n \n \n \n \n \n \n $m\n \n \n \n \n % change\n \n \n \n \n $m\n \n \n \n \n % change\n \n \n \n \n \n \n Actual\n \n \n \n \n \n CER\n \n \n 1\n \n \n \n \n \n Actual\n \n \n \n \n CER\n \n \n \n \n \n \n Total Revenue\n \n \n \n \n 19,207\n \n \n \n \n 8\n \n \n \n \n 10\n \n \n \n \n 6,578\n \n \n \n \n 3\n \n \n \n \n 3\n \n \n \n \n \n \n - Product Sales\n \n \n \n \n 18,879\n \n \n \n \n 9\n \n \n \n \n 11\n \n \n \n ...